| Pillar Breakdowns | USA Score | China Score | Net Advantage |
|---|---|---|---|
| 1. Supply Chain Control & Self-Sufficiency | 35 | 70 | 35 Points (China) |
| 2. Innovation Leadership & IP | 85 | 65 | 20 Points (USA) |
| 3. Regulatory & Trade Weaponization | 80 | 60 | 20 Points (USA) |
| 4. Geopolitical Alliances & Global Market Share | 75 | 65 | 10 Points (USA) |
| Composite Tech GTSI Score | 68.75 | 65.00 | USA +3.75 |
| Pillar Breakdowns | USA Score | China Score | Net Advantage |
|---|---|---|---|
| 1. Supply Chain Control & Self-Sufficiency | 25 | 85 | 60 Points (China) |
| 2. Innovation Leadership & IP | 90 | 55 | 35 Points (USA) |
| 3. Regulatory & Trade Weaponization | 65 | 70 | 5 Points (China) |
| 4. Geopolitical Alliances & Global Market Share | 65 | 75 | 10 Points (China) |
| Composite Healthcare GTSI Score | 61.25 | 71.25 | China +10.00 |
| Pillar Breakdowns | USA Score | China Score | Net Advantage |
|---|---|---|---|
| 1. Supply Chain Control & Self-Sufficiency | 40 | 95 | 55 Points (China) |
| 2. Innovation Leadership & IP | 65 | 85 | 20 Points (China) |
| 3. Regulatory & Trade Weaponization | 75 | 80 | 5 Points (China) |
| 4. Geopolitical Alliances & Global Market Share | 55 | 85 | 30 Points (China) |
| Composite Energy GTSI Score | 58.75 | 86.25 | China +27.50 |
| Strategic Sector | USA Composite Score | China Composite Score | Net Advantage | Battlefield Status |
|---|---|---|---|---|
| Defense and AI Technology | 68.75 | 65.00 | USA (+3.75) | Moderate Advantage |
| Healthcare Technology | 61.25 | 71.25 | China (+10.00) | Moderate Advantage |
| Energy Security | 58.75 | 86.25 | China (+27.50) | Absolute Dominance |
China's structural position is strengthening at a faster trajectory due to its systemic near-monopoly over midstream critical mineral processing and scaled green manufacturing ecosystems, which cannot be quickly or cheaply replicated by Western capital expenditures. While the United States retains an elite tier advantage in advanced electronic design automation and foundational artificial intelligence architectures, this software dominance remains structurally constrained by acute physical vulnerabilities in baseline pharmaceutical inputs and manufacturing chains. Consequently, heading into the late 2020s, the balance of asymmetric economic leverage is tilting toward China's hardware-centric, material supply chain framework over the United States' software-and-IP heavy model.